BioRestorative Therapies CEO Mark Weinreb was recently interviewed by financial personality and founder of NBT Equities Research, Tobin Smith, to discuss the life science company's medical procedures using cell and tissue protocols, specifically focusing on its "anti-biotech" business model and what the company is doing to positively impact the biotech industry.
"We've come up with a hybrid approach enabling us to basically efficiently and economically … develop an enormous amount of science and with relevant data and move projects along in a very quick manner. We've been able to leverage many assets that are out there and instead of building a huge infrastructure and going through money very quickly; we've been able to control all of that and come up with incredible scientific programs," Weinreb stated.
The interview includes an update on BRTX's ThermoStem™ Program, which is designed to develop treatments using brown fat stem cells for metabolic disorders and obesity. The program has a narrower focus of potentially preventing the onset of Type 2 diabetes.
Weinreb details how the company has made strides in this area through preclinical development based on animal data that shows how the processes occur.
The interview also highlights BRTX's brtxDISC™ Program designed for the re-transplantation of an individual's own stem cells into the disc area to repair the damaged area. This program is near ready for clinical trials. The non-invasive procedure is done in a physician's office within 30 minutes.
The interview in its entirety can be heard on the NBT Equities Research Web site here: direct.nbtequitiesresearch.com/video/nbt...-1
For more information, visit biorestorative.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net